Crystal structure analysis reveals the details of 4-(1H-imidazol-2-yl)pyrrolo[1,2-a]quinoxaline, indicating its unique properties.
C 14 H 10 N 4 , monoclinic, P 2 1 / n (no. 14), a = 9.9079(1) Å, b = 17.8256(3) Å, c = 13.1492(2) Å, β = 98.804(1)°, V = 2294.97(6) Å 3 , Z = 8, R gt ( F ) = 0.0364, wR ref ( F 2 ) = 0.0354, T = 299 K.
No takes yet. Share an insight, caveat, or question.
Liang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: